The journey towards accessible medical cannabis in Greece remains fraught with challenges, despite its legalisation in 2017. This article delves into the complexities and barriers faced by patients in accessing medical cannabis treatments.
Medical Cannabis Legalisation in Greece
Greece's journey with medical cannabis began in 2017, allowing the cultivation and production of products containing more than 0.3% THC. However, the path to accessibility and patient treatment has been hindered by regulatory and bureaucratic obstacles.
Key Barriers to Access
- Regulatory hurdles limiting patient access to cannabis products
- Lack of domestic production and the ban on imports of medical cannabis products
European Parliament's Involvement
Greek MEP Stelios Kouloglou has been vocal in the European Parliament, seeking clarity and uniformity in medical cannabis policies across Europe to ease patient access in Greece and beyond.
Addressing the European Commission
MEP Kouloglou's appeals to the European Commission focus on the need for fair competition and the free movement of goods within the EU, especially concerning medical cannabis products.
Impact of the Import Ban on Patients
The Greek government's decision to ban the import of medical cannabis products in 2021 has significantly affected patients, forcing many to resort to the black market for treatment.
Challenges Faced by Patients
- Difficulties in accessing quality-controlled cannabis products
- Risks associated with turning to unregulated sources
Comparative European Landscape
The situation in Greece highlights the broader issue of inconsistent cannabis policies across Europe, affecting patient access and the development of the medical cannabis industry.
Europe's Patchwork of Cannabis Regulations
A look at how varying legal frameworks across European countries impact the overall effectiveness of medical cannabis programmes.
